The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

Welcome to this week's edition of The Targeted Pulse, your clinical-focused wrap-up of the most impactful news and research ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

The vaccine doesn't prevent cancer from happening in the first place, but an early-phase trial found it could reduce the odds ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by ...

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.